###### Strengths and limitations of this study

-   The main strength of the study lies in its sample size, due to the fact that it is a nationwide study with one of the broadest samples to date in South Korea.

-   The study provided a recent information of the seroprevalence of antirubella IgG that have not been available at this scale before.

-   The huge sample size of this study allowed for precise information of the age-related seroprevalence of antirubella IgG and this study provides valuable information for establishing a catch-up vaccination programme in South Korea.

-   One limitation of this study was the lack of detailed clinical information; however, seroprevalence studies are an essential tool to monitor the efficacy of vaccination programmes, to understand population immunity and to identify populations at higher risk of infection.

Introduction {#s1}
============

Rubella disease is caused by rubella virus (belonging to the family Togaviridae and the only member of the genus *Rubivirus*).[@R1] Although most cases of infection lead to a mild, self-limiting measles-like disease, the real threat arises when rubella virus infects the fetus, particularly during the first trimester when infection can lead to miscarriage or congenital rubella syndrome.[@R1] Worldwide, over 100 000 babies are born with congenital rubella syndrome every year, and the WHO recommends that all countries that have not yet introduced a rubella vaccine should consider doing so using existing, well-established measles immunisation programmes.[@R2] The WHO Strategic Advisory Group of Experts on Immunization (SAGE) recommends an increased focus on improving national immunisation systems in general to better control rubella.[@R2] Under the Global Vaccine Action Plan 2011--2020, rubella is targeted for elimination in five WHO Regions by 2020.[@R3] As has been reported in Europe, suboptimal coverage levels in childhood (\<95%) can lead to a prolonged inter-epidemic period and to a paradoxical shift of disease incidence towards older age groups, including women of childbearing age, with a consequent increase of congenital rubella syndrome.[@R5] Serosurveys may represent an effective instrument to measure infection-induced and vaccine-induced immunity in a specific population, and serosurveys can effectively support strategies aimed at eliminating the disease.[@R5]

The incidence of rubella infection in South Korea was 107 cases in 2000 that decreased to 7 cases in 2017, corresponding to incidence rates below 0.1 per 100 000 persons according to the Infectious Diseases Surveillance Yearbook, 2017.[@R6] Although the exact number of cases for congenital rubella syndrome was not available for the surveillance book, 17 cases in 2010 of congenital rubella syndrome were reported, which using the Korean Classification of Disease code P350 for congenital rubella syndrome on the Healthcare Bigdata Hub by the Health Insurance Review and Assessment Service (HIRA).[@R7] According to the reported measles and rubella cases and incidence rates by WHO member states, 0--3947 confirmed rubella cases corresponding to incidence rates of 0--11.54 per 1 000 000 total population were reported in 2018 in the western pacific region.[@R8]

In Korea, a rubella vaccination programme using the measles, mumps in rubella (MMR) vaccine has been included in the national immunisation programme since 1985 for disease control and prevention.[@R9] A second MMR vaccine dose was introduced in 1997, and a catch-up measles-rubella (MR) vaccine for school-aged children was introduced in 2001.[@R9] In 2002, a two-dose MMR keep-up programme through the verification of vaccination history was introduced at elementary schools (6--7 years).[@R9] A new vaccination policy was formed by the 2012 Military Healthcare Service, and since then, MMR vaccines have been routinely administered to all new recruits early in basic training.[@R10] The national guidelines in Korea regarding ascertainment of rubella immunity are based on laboratory evidence for rubella antibodies and the Korea Centers for Disease Control and Prevention recommends that women of childbearing age whose antirubella specific IgG is negative should receive 1 dose of the MMR vaccine although they did have histories of rubella vaccination (total numbers of vaccination in one individual should be ≤3).[@R11]

Although there have been several studies on rubella in Korea, most of the studies have only been focused on surveillance of newly identified cases, seroprevalences of rubella IgG in children or had been conducted in the early 1990s.[@R9] Although a recent meta-analysis assessing global seroprevalence of rubella among pregnant and childbearing age women, no data from Korean populations were included in the study.[@R5] In a recent 16-year review of seroprevalence studies on rubella, only one Korean study on children and adolescents was included.[@R3] To our knowledge, no recent data have been collected on rubella immunisation status with rubella-specific IgG antibodies in Korean women of childbearing age in a large study population, which could provide basic knowledge on nationwide immunisation strategies. Green Cross Laboratories is one of the largest referral clinical laboratories throughout South Korea that has its own bio-logistics and provides clinical specimen analysis services including rubella-specific IgG antibody tests to nationwide clinics and hospitals. According to the provider data on the National Health Insurance Statistical Yearbook 2017 published by HIRA in South Korea, 1319 private obstetric clinics and 1433 hospitals with or without obstetric clinics are providing health services.[@R17] Among a total of 91 545 healthcare providing institutions (public and private), 4.1% (3746 institutions) were public or national provider institutions.[@R17] According to the review records of delivery by provider type in the same book, 89.9% (523/582) of delivery institutions nationwide were private obstetric clinics and hospitals.[@R17] Among the 358 285 deliveries carried out in 2017, 93.5% (335 119) were delivered in private obstetric clinics and hospitals.[@R17]

Therefore, in this study, we aimed to investigate the immunity against rubella and to share baseline data for future immunisation policies in South Korea. The aim of this study was to investigate the epidemiology of rubella immunisation status using serological assays for rubella-specific IgG antibodies in Korean women of childbearing age. In addition, we assessed rubella immunisation status according to year and age group.

Materials and Methods {#s2}
=====================

Participants' involvement and data collection {#s2-1}
---------------------------------------------

No patients were involved in the development of the research question or the outcome measures, nor were they involved in developing plans for design or implementation of the study. No patients were asked for advice regarding the interpretation or writing of results. There are no plans to disseminate the study results to the relevant patient community.

Study populations {#s2-2}
-----------------

Between January 2010 and December 2017, test results from Korean women aged 15--49 years who had visited an obstetric private clinics and hospitals (nationwide institutions) and had requested rubella-specific IgG antibody tests from Green Cross Laboratories were obtained from the laboratory information system. Missing data for age, sex and geographic regions were excluded. Test results from women whose tests were duplicated were excluded. All data were anonymised before being transferred to analysis for age-specific, year-specific, birth cohort and geographical region-specific antirubella IgG seroprevalences. This study was conducted according to guidelines in the Declaration of Helsinki.

Data collection {#s2-3}
---------------

Annual incidence of rubella infection in South Korea was obtained from reported cases in the Infectious Diseases Surveillance Yearbook, 2017 by the Korea Centers for Disease Control and Prevention.[@R6] Data for the incidence of congenital rubella syndrome was obtained from the Healthcare Bigdata Hub by HIRA using Korean Classification of Disease code P350 in South Korea.[@R7]

Analytical procedures {#s2-4}
---------------------

All serum samples were tested for antirubella IgG using a chemiluminescent microparticle immunoassay (Architect i2000SR, Abbott Diagnostics, Abbott Park, Illinois, USA) according to the manufacturer\'s instructions. For the rubella IgG assay, the presence of ≥10 IU/mL was defined as 'positive'. Antibody levels of 0.0--4.9 IU/mL were defined as 'negative', and antibody levels between 5.0 and 9.9 IU/mL were defined as 'equivocal'. During the 8-year study period, the laboratory protocol was maintained without any changes and all tests requested for antirubella specific IgG were analysed automatically and tested once without retest.

Definition {#s2-5}
----------

Positive rubella-specific IgG results are indicative of past exposure to rubella virus or being vaccinated.[@R18] Women who had 'negative' results were defined as 'unimmunised'. Women were classified as 'immune' if their antirubella IgG was positive or showed equivocal results.[@R18] Birth cohorts were defined based on the vaccination programme: pre-catch-up, 1976--1984; catch-up, 1985--1993 and keep-up, ≥1994.[@R9] The pre-catch-up (1976--1984) cohort was women who had presumptively limited MMR vaccination coverage with only one dose provided by the public programme. The catch-up (1985--1993) cohort was woman who had limited MMR vaccination coverage but were given the MR vaccine during the 2001 catch-up campaign.[@R9] The keep-up (≥1994) cohort was women who were candidates for the keep-up programme.[@R9]

Statistical analysis {#s2-6}
--------------------

Categorical variables are presented as frequencies and percentages. The χ² test was used to compare categorical variables. The Cochran-Armitage test for trend was performed to evaluate the seroprevalence of antirubella IgG by year and cohort. Multivariable-adjusted logistic regression models were used to estimate the OR of being immune to rubella based on the results of the antirubella IgG seroprevalence test for the tested years, age, birth cohort and geographic region in South Korea. Variables with univariate p values less than 0.05 were included as adjusted variables for the multivariable analysis. Statistical analysis was executed using MedCalc Statistical Software V.18.5 (MedCalc Software bvba, Ostend, Belgium). P values were considered significant at the 0.05 level.

Results {#s3}
=======

General characteristics of the study population {#s3-1}
-----------------------------------------------

Between January 2010 and December 2017, antirubella IgG test results from 328 426 Korean women age 15--49 years who had visited obstetric private clinics (from 1438 institutions nationwide) and had requested rubella-specific IgG antibody tests from Green Cross Laboratories were obtained from the laboratory information system and included in the study. The numbers for antirubella IgG results for the study subjects by each year and age group are summarised in [table 1](#T1){ref-type="table"}.

###### 

Test results for antirubella IgG by each tested-year and age for 328 465 Korean women tested for rubella IgG antibodies

  Test year   15--20 years   21--30 years   31--40 years   41--49 years                                                                                                    
  ----------- -------------- -------------- -------------- -------------- ------ -------- -------- --------- -------- -------- --------- --------- ------- ------- ------- -------
  2010        8              48             312            368            1332   2499     13 628   17 459    1640     1601     16 691    19 932    87      102     623     812
              2.2%           13.0%          84.8%          9.4%           7.6%   14.3%    78.1%    14.1%     8.2%     8.0%     83.7%     10.4%     10.7%   12.6%   76.7%   8.6%
  2011        25             64             451            540            1717   3024     13 376   18 117    2167     2600     17 668    22 436    120     103     687     910
              4.6%           11.9%          83.5%          13.8%          9.5%   16.7%    73.8%    14.6%     9.7%     11.6%    78.8%     11.8%     13.2%   11.3%   75.5%   9.6%
  2012        30             105            439            574            1381   2899     13 388   17 668    2321     3438     19 407    25 166    225     137     1125    1487
              5.2%           18.3%          76.5%          14.7%          7.8%   16.4%    75.8%    14.2%     9.2%     13.7%    77.1%     13.2%     15.1%   9.2%    75.7%   15.8%
  2013        23             113            379            515            1195   2491     11 989   15 675    2477     3867     18 106    24 450    135     106     875     1116
              4.5%           21.9%          73.6%          13.2%          7.6%   15.9%    76.5%    12.6%     10.1%    15.8%    74.1%     12.8%     12.1%   9.5%    78.4%   11.8%
  2014        35             100            405            540            778    2032     11 793   14 603    2142     3662     17 906    23 710    111     108     919     1138
              6.5%           18.5%          75.0%          13.8%          5.3%   13.9%    80.8%    11.8%     9.0%     15.4%    75.5%     12.4%     9.8%    9.5%    80.8%   12.1%
  2015        29             84             398            511            674    2032     11 596   14 302    2407     4361     18 467    25 235    137     91      997     1225
              5.7%           16.4%          77.9%          13.1%          4.7%   14.2%    81.1%    11.5%     9.5%     17.3%    73.2%     13.2%     11.2%   7.4%    81.4%   13.0%
  2016        39             79             389            507            651    1887     11 152   13 690    2573     4532     18 304    25 409    142     105     1029    1276
              7.7%           15.6%          76.7%          13.0%          4.8%   13.8%    81.5%    11.0%     10.1%    17.8%    72.0%     13.3%     11.1%   8.2%    80.6%   13.5%
  2017        39             78             228            345            779    1985     9922     12 686    2689     4709     17 151    24 549    162     118     1196    1476
              11.3%          22.6%          66.1%          8.8%           6.1%   15.6%    78.2%    10.2%     11.0%    19.2%    69.9%     12.9%     11.0%   8.0%    81.0%   15.6%
  Total       228            671            3001           3900           8507   18 849   96 844   124 200   18 416   28 770   143 700   190 886   1119    870     7451    9440
              5.8%           17.2%          76.9%                         6.8%   15.2%    78.0%              9.6%     15.1%    75.3%               11.9%   9.2%    78.9%   

E, equivocal; N, negative; P, positive.

Rubella immunity in Korean women of childbearing age {#s3-2}
----------------------------------------------------

The overall proportion of IgG-negative women who were defined as 'unimmunised' was 8.6%, and the overall proportion of IgG-equivocal women was 15.0% and IgG-positive women was 76.4%. Rubella-specific IgG antibody test results with an annual incidence of rubella infection and congenital rubella syndrome from surveillance data by year are summarised in [figure 1](#F1){ref-type="fig"}. There were significant differences in the rate of unimmunised women during the 8-year study period (p\<0.05), although there was no significant trend (p\>0.05). There was a decrease in the rate of women who had positive rubella-specific IgG antibody results (from 81.0% in 2010 to 73.0% in 2017, p\<0.05) and an increase in the rate of women who had 'equivocal' results from 2010 to 2017 (11.0% in 2010 to 17.6% in 2017, p\<0.05, [figure 1](#F1){ref-type="fig"}). There were significant differences in the rate of unimmunised women among different age groups, cohorts and geographic regions (p\<0.05). For example, less than 1000 women had been tested for antirubella IgG in the Gangwon province and Ulsan.

![Rubella-specific IgG antibody test results with annual incidence of rubella infection and congenital rubella syndrome from surveillance data by year (2010--2017). Percentage of rubella specific IgG results in this study (left axis) and numbers of cases for incidence of rubella from surveillance data (right axis) are plotted against years tested.](bmjopen-2019-030873f01){#F1}

Multivariable--adjusted logistic regression models showed that the odds of being immune to rubella (positive and equivocal results of antirubella IgG tests) were decreased in 2017 compared with 2010 (OR 0.63, 95% CI 0.60 to 0.67, p\<0.0001) and women in their 40s (OR 0.85, 95% CI 0.79 to 0.90, p\<0.0001, [table 2](#T2){ref-type="table"}). Among different cohorts, catch-up (being born in 1985--1993) and keep-up (born ≥1994) cohorts had higher ORs for being immune to rubella compared with pre-catch-up cohorts (born in 1976--1984, p\<0.0001). Among different geographic regions, women living in Incheon, Busan, South Gyeongsang, North and South Jeolla and Jeju provinces had lower ORs and women living in Sejong city and Daejeon had higher ORs for being immune to rubella in comparison with women living in Seoul (p\<0.0001).

###### 

Association between seroprevalence of antirubella IgG (being immune to rubella)\* and population characteristics

                                Total     Immune    Univariable logistic regression   Multivariable logistic regression                                                   
  ----------------------------- --------- --------- --------------------------------- ----------------------------------- -------------- ---------- ------ -------------- ----------
  Tested year                                                                                                                                                             
   2010                         38 571    35 504    92.0                                                                                                                  
   2011                         42 002    37 973    90.4                              0.81                                0.78 to 0.86   \<0.0001   0.79   0.75 to 0.83   \<0.0001
   2012                         44 895    40 938    91.2                              0.89                                0.85 to 0.94   \<0.0001   0.85   0.81 to 0.89   \<0.0001
   2013                         41 756    37 926    90.8                              0.86                                0.81 to 0.90   \<0.0001   0.78   0.74 to 0.82   \<0.0001
   2014                         39 991    36 925    92.3                              1.04                                0.99 to 1.10   0.1368     0.91   0.86 to 0.96   0.0003
   2015                         41 273    38 026    92.1                              1.01                                0.96 to 1.07   0.6586     0.84   0.80 to 0.89   \<0.0001
   2016                         40 882    37 477    91.7                              0.95                                0.90 to 1.00   0.0520     0.75   0.72 to 0.79   \<0.0001
   2017                         39 056    35 387    90.6                              0.83                                0.79 to 0.88   \<0.0001   0.63   0.60 to 0.67   \<0.0001
  Age of women                                                                                                                                                            
   15--20 years                 3900      3672      94.2                                                                                                                  
   21--30 years                 124 200   115 693   93.2                              0.84                                0.74 to 0.97   \<0.0001                         
   31--40 years                 190 886   172 470   90.4                              0.58                                0.51 to 0.67   \<0.0001                         
   41--49 years                 9440      8321      88.1                              0.46                                0.40 to 0.54   \<0.0001   0.85   0.79 to 0.90   \<0.0001
  Cohort                                                                                                                                                                  
   Pre-catch-up (1976--1984)    228 176   205 536   90.1                                                                                                                  
   Catch-up (1985--1993)        94 056    88 887    94.5                              1.89                                1.84 to 1.95   \<0.0001   1.99   1.92 to 2.05   \<0.0001
   Keep-up (≥1994)              6194      5733      92.6                              1.37                                1.24 to 1.51   \<0.0001   1.50   1.36 to 1.65   \<0.0001
  Geographic locations                                                                                                                                                    
   Seoul                        65 380    59 821    91.5                                                                                                                  
   Gyeonggi Province            131 157   120 183   91.6                              1.02                                0.98 to 1.05   0.3078                           
   Incheon                      9611      8747      91.0                              0.94                                0.87 to 1.01   0.1111     0.93   0.86 to 1.00   0.0382
   Gangwon Province             703       654       93.0                              1.24                                0.93 to 1.66   0.1478                           
   Sejong City                  3859      3623      93.9                              1.43                                1.25 to 1.63   \<0.0001   1.20   1.05 to 1.37   0.0076
   Daejeon                      12 496    11 553    92.5                              1.14                                1.06 to 1.22   0.0004     1.07   1.00 to 1.15   0.0484
   North Chungcheong Province   11 186    10 306    92.1                              1.09                                1.01 to 1.17   0.0252                           
   South Chungcheong Province   8390      7710      91.9                              1.05                                0.97 to 1.14   0.2178                           
   Daegu                        14 781    13 473    91.2                              0.96                                0.90 to 1.02   0.1739                           
   Ulsan                        660       625       94.7                              1.66                                1.18 to 2.34   0.0037                           
   North Gyeongsang Province    2075      1891      91.1                              0.96                                0.82 to 1.11   0.5577                           
   South Gyeongsang Province    4426      3994      90.2                              0.86                                0.78 to 0.95   0.0039     0.85   0.77 to 0.95   0.0023
   Busan                        12 574    11 376    90.5                              0.88                                0.83 to 0.94   0.0002     0.86   0.81 to 0.91   \<0.0001
   Gwangju                      2035      1845      90.7                              0.90                                0.78 to 1.05   0.1848                           
   North Jeolla Province        11 911    10 890    91.4                              0.99                                0.92 to 1.06   0.8031     0.93   0.87 to 0.99   0.0213
   South Jeolla Province        13 621    12 233    89.8                              0.82                                0.77 to 0.87   \<0.0001   0.79   0.75 to 0.84   \<0.0001
   Jeju Province                23 561    21 232    90.1                              0.85                                0.81 to 0.89   \<0.0001   0.83   0.79 to 0.87   \<0.0001

\*Positive and equivocal results of antirubella specific IgG test results were defined as 'immune' in this study.[@R18]

Discussion {#s4}
==========

In this study, we investigated the seroprevalence of rubella in Korean women of childbearing age within the past 8 years. The strength of this study was the large study population over a long study period (8 years) and the novelty of the study population (Korean women of childbearing age were assessed for the first time in Korea). Because previous studies focused on the different measurement methods and immunisation status, this suggested that equivocal results might be due to being immune to rubella infection;[@R18] thus, the authors focused on and analysed factors associated with those whose antirubella IgG results were negative.

Understanding the spread of infectious diseases and designing optimal control strategies is a major goal of public health.[@R20] In the present study, the seronegativity prevalence was 8.6% in Korean women of childbearing age. A recent 16-year review of seroprevalence studies on rubella assessing 97 articles between January 1998 and June 2014 had reported that seroprevalence ranged from 53.0% to 99.3% for rubella studies.[@R3] A recent meta-analysis of rubella among pregnant and childbearing age women had reported that approximately 88% of the studies conducted on pregnant women had reported a seronegativity rate \>5%, and the pooled rubella seronegativity prevalence was 9.3%.[@R5] The study had reported that global seronegativity prevalence was of concern, considering that WHO set the rubella susceptibility threshold at 5% for women of childbearing age. Previous studies that had been included in the meta-analysis had used more than 1000 subjects and had been published within the past 10 years are summarised in [table 3](#T3){ref-type="table"}.

###### 

Previous studies on rubella seronegativity in women that included more than 1000 subjects and were published within the past 10 years, grouped by WHO region

  WHO region   Publication year   N         Country             Seronegativity (%)   Population   Reference                            Measurement method
  ------------ ------------------ --------- ------------------- -------------------- ------------ ------------------------------------ ------------------------------------------------------------------------------
  AFR          2009               7430      South Africa        6.2                  WCBA         Schoub *et al* [@R26]                Bio-Rad Platelia Rubella IgG ELISA
  AMR          2009               8939      Brazil              28.4                 Pregnant     Inagaki *et al* [@R27]               Q-Preven IgG-DBS kit
  AMR          2011               9610      Brazil              11.6                 Pregnant     Artimos de Oliveira *et al* [@R28]   Beckman Coulter Access RUBELLA IgG ChLIA or bioMérieux VIDAS RUB IgG II ELFA
  AMR          2016               54 717    Brazil              4.5                  Pregnant     Avila Moura *et al* [@R29]           Q-Preven IgG-DBS kit
  AMR          2009               5783      Canada              7.0                  Pregnant     McElroy *et al* [@R30]               Hemagglutination inhibition test
  AMR          2013               459 963   Canada              4.4                  WCBA         Lim *et al* [@R31]                   Abbott AxSYM Rubella IgG MEIA
  AMR          2015               157 763   Canada              15.9                 Pregnant     Lai *et al* [@R32]                   Abbott ARCHITECT Rubella IgG CMIA
  EMR          2014               4062      Kuwait              6.8                  Pregnant     Madi *et al* [@R33]                  Abbott ARCHITECT Rubella IgG CMIA
  EMR          2013               2284      Morocco             9.8                  Pregnant     Belefquih *et al* [@R34]             Siemens Enzygnost Anti-Rubella-Virus IgG EIA
  EMR          2014               10 276    Saudi Arabia        8.7                  Pregnant     Alsibiani *et al* [@R35]             Dade Behring ELISA BP III
  EUR          2012               424 876   England             2.6                  Pregnant     Byrne *et al* [@R36]                 Microgen Mercia Rubella G EIA
  EUR          2013               1090      Germany             1.6                  Pregnant     Enders *et al* [@R37]                Hemagglutination inhibition test
  EUR          2013               74 810    Ireland             6.2                  Pregnant     O'Dwyer *et al* [@R38]               Method not described
  EUR          2012               2385      Italy               8.0                  Pregnant     De Paschale *et al* [@R39]           DiaSorin ETI-RUBEK-G PLUS EIA
  EUR          2015               22 681    Spain               5.9                  Pregnant     Vilajeliu *et al* [@R40]             Siemens ADVIA Centaur Rubella G ChLIA
  EUR          2010               41 637    Sweden              4.2                  Pregnant     Kakoulidou *et al* [@R41]            Abbott AxSYM Rubella IgG MEIA
  EUR          2009               1972      Turkey              3.9                  Pregnant     Tamer *et al* [@R42]                 Abbott AxSYM Rubella IgG MEIA
  EUR          2012               5959      Turkey              1.9                  Pregnant     Uysal *et al* [@R43]                 bioMérieux VIDAS RUB IgG II ELFA
  EUR          2011               11 987    UK                  4.4                  Pregnant     Matthews *et al* [@R44]              DiaSorin ETI-RUBEK-G EIA
  EUR          2016               19 046    UK                  6.3                  Pregnant     Ogundele *et al* [@R45]              Roche E602 MODULAR analyzer
  SEAR         2011               2224      Nepal               9.2                  WCBA         Upreti *et al* [@R46]                Enzygnost Anti-Rubella-Virus IgG EIA
  SEAR         2014               1988      Vietnam             28.9                 Pregnant     Miyakawa *et al* [@R47]              bioMérieux Mini VIDAS EIA
  WPR          2008               1020      Australia           2.7                  WCBA         Nardone *et al* [@R48]               Siemens Enzygnost Anti-Rubella-Virus IgG EIA
  WPR          2008               2741      Japan               6.7                  Pregnant     Okuda *et al* [@R49]                 Hemagglutination inhibition test
  WPR          2013               13 924    Japan               2.7                  Pregnant     Hanaoka *et al* [@R50]               Hemagglutination inhibition test
  WPR          2014               20 363    Japan               4.7                  Pregnant     Yamada *et al* [@R51]                Hemagglutination inhibition test
  WPR          2017               782 293   China               33.8                 WCBA         Liu *et al* [@R52]                   Method not described
  WPR          2011               43 640    Taiwan              10.9                 Pregnant     Lin *et al* [@R53]                   Abbott AxSYM Rubella IgG MEIA and Beckman Coulter Access RUBELLA IgG ChLIA
  WPR          2012               14 090    Taiwan              6.5                  Pregnant     Lin *et al* [@R54]                   Abbott AxSYM Rubella IgG MEIA
  WPR          2019               327 637   Republic of Korea   8.7                  WCBA         This study                           Abbott ARCHITECT Rubella IgG CMIA

AFR, Africa region; AMR, American region; EMR, Eastern Mediterranean Region; EUR, European region; SEAR, South-East Asian region; WCBA, women of childbearing age; WPR, Western Pacific region.

The seroprevalence of rubella in Korean populations was assessed previously in infants, children and adolescents.[@R12] One study on 5393 students from eight elementary schools in the Gyeonggi province, Korea in 1993, 1996 and 1996 had reported that the age-adjusted rubella susceptibility rate was 22.9%.[@R14] Another study performed during the same study period had reported that rubella antibody loss rates were 14.3%--15.8% in Korean children.[@R12] In a 2005 population-based survey in Nonsan, Korea, age-appropriate immunisation among urban-rural children aged 24--35 months had reported that the age-appropriate MMR immunisation rate was 61.1%--97.4%.[@R16] A recent study conducted between September 2009 and December 2010 assessing seroprevalence of rubella in 295 infants and 80 of their mothers had reported that seropositive rates were 22.4% in infants and 98.8% in mothers (79/80).[@R13] In that study, because none of the infants had a history of MMR vaccination, natural infection or contact with an infected person, it was assumed that specific antibodies were passed from their mothers to their infants.[@R13] Moreover, among the 80 mothers, 55 (68.8%) had experienced either immunisation or past rubella infection.[@R13]

The historical immunisation coverage in preschool children right before admission to elementary school, which was evaluated based on a telephone survey, reported 99.5% in 2001 and 97.3% of school-aged children (catch-up cohort) were vaccinated with the MR vaccine.[@R22] According to the Infectious Disease Surveillance Yearbook 2017, published by the Korean Ministry of Health and Welfare and the Korean Centers for Disease Control and Prevention, the incidence rate of rubella from 2001 to 2017 decreased (from 0.17 per 100 000 population in 2001 to 0.01 per 100 000 population in 2017).[@R6] In this study, ORs for being immune to rubella infection were higher in the catch-up (born 1985--1993) and keep-up (born ≥1994) cohorts than in pre-catch-up cohorts (born 1976--1984) which suggests that catch-up and keep-up immunisation was effective.[@R22] The vaccine coverage rate was maintained at \>95% from 2010 to 2017 in South Korea (ranges 97.0% in 2012 to 99.8% in 2010).[@R22] No rubella outbreak had been reported in South Korea over 8 years (2010--2017) according to the Infectious Disease Surveillance Yearbook. Among the different age groups, older women were more likely to have negative IgG results and no protection from rubella infection. Women in their 30s had the lowest rate of IgG+ results in this study. According to recent data from Korean Statistical Information (KOSIS), the average maternal age at delivery for Korean women was 32.4 years in 2016. Because of this, public health efforts should be focused on catch-up activities. The results of this study could be used as basic knowledge to support strengthening disease control and prevention of rubella, including a nationwide immunisation programme.

In South Korea, national guidelines in force to control and prevention measles and rubella include national immunisation programme and active disease surveillance system.[@R2] MMR vaccination has been covered by national health insurance that provides free of charge immunisation to all children aged ≤12 years, and clinical laboratory screening for rubella immunisation status using antirubella-specific IgG tests in pregnant women has been covered by the national health insurance free of charge for women visiting obstetrics clinics.[@R17] Susceptible woman of childbearing age is indeed a priority, and public health efforts should be focused on catch-up activities in order to reduce the rate of susceptible young adults, especially for all women of childbearing age.[@R23] Gynaecologists and general practitioners should be encouraged to propose rubella screening for women of childbearing age before they become pregnant to identify those women who lack rubella antibodies, whether acquired as the result of vaccination or a natural infection.[@R23] Finally, active surveillance from laboratories that perform rubella immunity testing should be planned; laboratories should notify the Public Health Authority about every woman of childbearing age with a negative test, and the Public Health Authority should engage these women to promote immunisation against rubella.[@R23] Serological surveillance is an important tool for the evaluation of vaccination programmes and avoids the limitations of passive disease reporting systems; this is one of the entry points for congenital rubella syndrome surveillance, where gaps limit the ability to monitor progress towards its elimination.[@R23]

In this study, women living in Sejong city were the most protected from rubella infection. In early 2007, the South Korean government had created a special administrative district from parts of the South Chungcheong and North Chungcheong provinces, near Daejeon, to relocate nine ministries and four national agencies from Seoul. Various government programmes for encouraging more births, such as incentives, in different regions may have affected the results.[@R4] In this study, less than 1000 women had been tested for antirubella IgG in the Gangwon province and Ulsan. This may affect the per cent seropositivity of antirubella IgG in the present study. Future studies are needed to define the effect of regional differences of government strategies on rubella seroprevalences.

One limitation of this study was the lack of clinical information, such as vaccination history or contact history with rubella-infected individuals. The results of this study were prone to ascertainment bias because the study population was based on mostly private obstetric clinics; thus, results might be different from those obtained from individuals using national or public healthcare providing institutions, although the use of a population-based study minimised selection bias.[@R24] Because the exact proportions of pregnant women in Korea who used public health facilities to test for antirubella IgG, and their sociodemographics as well as rubella vaccine coverage among the population seeking healthcare from private and public sectors and the proportion of pregnant women as well as the general population seeking care from the private sector across provinces were not available, future studies to evaluate those factors associated with rubella control and prevention are needed. However, we do not yet understand what surrogate markers, other than antibodies, show longer-term cell-mediated immunity and protection from disease.[@R1] Seroprevalence studies are an essential tool to monitor the efficacy of vaccination programmes, to understand population immunity and to identify populations at higher risk of infection.[@R25] This study is a cross-sectional study and merely descriptive analyses were adopted in this study. The results of this study were prone to ascertainment bias. The present study did not include men, women with older ages or foreigners living in South Korea. Therefore, the findings are not generalisable to these groups. A systems-level approach to understanding the development and maintenance of acute and long-term immunity to rubella and a rubella-containing vaccine is needed.[@R1]

Conclusion {#s5}
==========

In conclusion, this study investigated immunisation status of rubella among Korean women of childbearing age. Considering the immunisation status by age group and the increased prevalence of women with equivocal results, future public health efforts should be focused on catch-up activities. The results of this study could be used as foundational knowledge for strengthening disease control and prevention of rubella, including a nationwide immunisation programme.
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